Pharma Tips

Abbott to Acquire Veropharm

By: Pharma News | Views: 1596 | Date: 25-Jun-2014

Abbott (NYSE: ABT) has announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer. Under the terms of the agreement, Abbott will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between 13.6 billion rubles and 17 billion rubles (or a range of approximately $395 million to $495 million U.S. dollars) depending on Garden Hills' share ownership of Veropharm at time of close. Garden Hills cur

Abbott to Acquire Veropharm

 

Abbott

Abbott (NYSE: ABT) has announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer. Under the terms of the agreement, Abbott will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between 13.6 billion rubles and 17 billion rubles (or a range of approximately $395 million to $495 million U.S. dollars) depending on Garden Hills' share ownership of Veropharm at time of close. Garden Hills currently owns more than 80 percent of Veropharm but is expected to own more than 95 percent by the time the transaction closes. Pursuant to the agreement, Abbott will also assume net debt of 4.7 billion rubles (or approximately $136 million U.S. dollars).

Abbott to Acquire Veropharm

Abbott has had a presence in Russia for nearly 40 years and, in line with the company's long-term commitment to growing global health care markets and capabilities, is committed to providing a reliable supply of its health care products to Russian patients.

Through this acquisition Abbott will obtain a portfolio of medicines that is well aligned with its current pharmaceutical therapeutic areas of focus in women's health, central nervous system, cardiovascular, and gastroenterology, while also adding an offering in the field of oncology.

Upon completion of the transaction, Abbott would also establish a manufacturing presence in Russia through its ownership of Veropharm's existing production facilities as well as a new state-of-the-art manufacturing facility that is currently under construction by Veropharm. Abbott intends to utilize its manufacturing expertise to expand Veropharm's capabilities and enhance the existing infrastructure.

Under terms of the agreement, the purchase price Abbott pays for Garden Hills is determined based on the percentage of Veropharm shares owned by Garden Hills at the time Abbott purchases Garden Hills. If Garden Hills owns 100 percent of the shares of Veropharm at that time, the total purchase price would be 17 billion rubles (or approximately $495 million U.S. dollars). Abbott will also assume net debt of 4.7 billion rubles (or approximately $136 million U.S. dollars).

Abbott plans to fund the transaction with cash on the balance sheet.

Abbott expects the acquisition to add approximately $150 million U.S. dollars in sales in 2015. The transaction is expected to close in the fourth quarter and will not impact Abbott's ongoing earnings-per-share guidance for 2014. The transaction is subject to customary closing conditions and regulatory approvals.

About Veropharm
Veropharm is one of the largest Russian pharmaceutical manufacturers. The company's production facilities comprise three pharmaceutical manufacturing sites in Pokrov, Belgorod and Voronezh. The company's product portfolio includes over 100 pharmaceutical products. Veropharm employs more than 2,000 people.

About Abbott
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.

Abbott has been operating in Russia since 1978 with its Russian operations headquartered in Moscow.

Previous Page Next Page

People Searching On This Page:
  • Lupin Limited
  • piramal

Related Pages


Piramal Enterprises acquires Mallinckrodt's Pharma Products for $203 million

Piramal Enterprises acquires Mallinckrodt's Pharma Products for $203 million

News | Pharma Companies
Date:
31-Jan-2017  Views: 806

Ajay Piramal led Piramal Enterprises has acquired a portfolio of anti-spasticity and pain management drugs from US based drug maker Mallinckrodt in an ...
Sun Pharma to acquire Russian firm Biosintez for $24 million

Sun Pharma to acquire Russian firm Biosintez for $24 million

News | Pharma Companies
Date:
29-Nov-2016  Views: 2741

Sun Pharmaceutical Industries Ltd has inked definitive agreements to acquire 85.1% stake in Russian company, JSC Biosintez, for $24 million, a move ai ...
Abbott to Acquire Alere, becoming leader in point of care testing

Abbott to Acquire Alere, becoming leader in point of care testing

News | Pharma Companies
Date:
05-Feb-2016  Views: 1250

Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's glo ...
Abbott Acquires Piramal's Domestic Drug Biz

Abbott Acquires Piramal's Domestic Drug Biz

News | Pharma Companies
Date:
18-Oct-2013  Views: 1634

"Abbott announced a definitive agreement with Piramal Healthcare limited to acquire full ownership of Piramal's Healthcare solutions for an upfront pa ...
Abbott invites QA Officer Analytical

Abbott invites QA Officer Analytical

Jobs | Quality Assurance | Gujarat
Date:
07-Oct-2012  Views: 6914

Abbott India Limited is a subsidiary of Abbott Laboratories, USA, a global, iversified health care company devoted to the discovery, development, manu ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

11  + 2 =     
Comments
People Searched About:
Lupin Limited   |   Piramal   |  
Google : 77 times | Yahoo : 22 times | Bing : 24 times |